

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145

Status	RECRUITING
Phase	Phase 2
Sponsor	Beth Israel Deaconess Medical Center
Enrollment	242 participants

Key Eligibility Criteria

Inclusion (5)

- e18yrs old on the day of study consent;
- Finasteride has been recommended for treatment of BPH by a physician;
- PSA <20ng/ml within the last six months;
- Willingness to maintain any current genitourinary medications (e.g., beta agonists, alpha blockers, anticholinergics);
- Patient is able and willing to provide written informed consent.

Exclusion (16)

- Active or past history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis;
- Previous diagnosis with any prostatic malignancy or precancerous lesions (atypical glandular foci);
- History of pelvic radiation;
- Actively receiving intravesical therapy for bladder cancer;
- Received treatment with any demethylating medications (azacitidine, decitabine, zebularine, guadecitabine, hydralazine);
- ... and 11 more (see full listing online)

Locations (1 total)

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States